Description
Scope of the Report The report titled“ Global PAH Market: Trends and Opportunities( 2015-2019)”, analyzes the potential opportunities and significant trends in the global Pulmonary Arterial Hypertension( PAH) market. The market size and forecast in value terms for global PAH market has been provided for the period 2010 to 2019, considering 2014 as the base year. The report also provides the compounded annual growth rate(% CAGR) for the forecast period 2015 to 2019. Over the next five years, Global PAH market revenue is forecasted to remain stable due to patent expiries and launch of new drugs.
Request a sample of this report @ http:// www. orbisresearch. com / contacts / request-sample / 185293.
The report provides detailed analysis of the global PAH market sizing and growth by type for the period 2010-2014. The market is further segment by drug mechanism and different dosage forms. The analysis of PAH individual drugs sales are also provided in the report.
The report profiles key market players such as Actelion Ltd., United Therapeutics Ltd. and SteadyMed Ltd. on the basis of attributes such as company overview, recent developments, strategies adopted by the market leaders to ensure growth, sustainability, financial overview and recent developments.
Purchase a copy of Global Pulmonary Arterial Hypertension( PAH) Market visit @ http:// www. orbisresearch. com / contact / purchase / 185293 For more information contact sales @ orbisresearch. com.
Company Coverage Actelion Limited United Therapeutics Limited SteadyMed Limited
PAH Drug Mechanism Endothelin Receptor Antagonists( ERA) PDE 5 Inhibitors Prostacyclins sGC Stimulator
Executive Summary Pulmonary Arterial Hypertension( PAH) is a disease in which high blood pressure occurs in the right ventricle of the heart and the pulmonary arteries that supply blood to the lungs. The increase in pressure is caused by constriction and narrowing of the small pulmonary arteries. In 2005, standard of care was characterized by intravenous treatment aimed at reducing symptoms, not addressing root cause. Now, new treatments are available that go beyond symptom management to treat the underlying cause of PAH. With advancement in the standard of care, patients are able to maintain active lifestyles with a reduced risk of serious heart events associated with PAH.
www. orbisresearch. com; + 1( 214) 884-6817; + 9120-64101019